BION-1301 is a first-in-class humanized antibody targeting APRoliferationInducing Ligand (APRIL). APRIL, TNP-Ficoll in Groups 5 to 8 was administered to assess the PK/PD effect of BION-1301 on the treatment of B-cell lymphomas. Blood. 2011 Jun 23;117(25):6856-65


BION-1301 is a first-in-class humanized antibody targeting APRoliferationInducing Ligand (APRIL, TNFSF13). APRIL is a ligand for the receptors BCMA and TACI and mediates important B-cell functions including activation, survival and maturation. APRIL drives expression of PD-L1, IL-10, VEGF and TGFβ forcing an immunosuppressive phenotype on BCMA+ cells. APRIL also activates STAT3 and PI3K pathways contributing to treatment and was generally characterized by a low clearance and limited distribution, as typical for antibodies. Circles (gray; BION-1301), squares (black; control) or triangles (red; control) represent the median of the total IgG level in cynomolgus monkey serum samples. For detection of anti-drug antibodies (ADA) an ELISA assay was used. Serum samples were added to a 96-well microtiter plate coated with BION-1301 and an anti-idiotype antibody. The captured analyte (BION-1301) was detected by a colorimetric ELISA method. Serum samples were added to a 96-well microtiter plate coated with BION-1301 and an anti-idiotype antibody. The captured analyte (BION-1301) was detected by a colorimetric ELISA method. Serum samples were added to a 96-well microtiter plate coated with BION-1301 and an anti-idiotype antibody. The captured analyte (BION-1301) was detected by a colorimetric ELISA method.